CMEI Policy Alert from Pacific Research Institute

View this email in your browser ([link removed])
[link removed]
New CMEI Issue Brief on Biosimilars Gains National Media Attention

July 19, 2019

PRI's new issue brief by Dr. Wayne Winegarden - "Incenting Competition to Reduce Drug Spending: The Biosimilar Opportunity" has received significant national media attention since its release.

Politico's "Prescription Pulse" newsletter, which is a very widely read newsletter highlighting all of the top news relating to the pharmaceutical industry, ran an item on the brief in its July 16 edition. (Click here to read ([link removed]) )

Also, the study was featured as the No. 4 item in the "Vitals," the daily newsletter on politics and policy from Axios. (Click here to read ([link removed]) )
Report: Growing Biosimilar Market Could Save Billions in Spending

Fierce Healthcare | Paige Minemyer
July 19, 2019

. . . Wayne Winegarden, director of the institute’s Center for Medical Economics and Research and the report’s author, told FierceHealthcare that if there’s room to develop a strong generic drug market, the same can be said for biosimilar products.

“That is probably one of the most exciting ways that we’re not talking about to control drug costs,” Winegarden said.

Over a decade, a 25% market share for biosimilars could save $24.7 billion in healthcare spending, according to the report. The number increases to $48 billion in a decade for a 50% market share and $71.7 billion for a 75% market share.

Read more . . . ([link removed])
------------------------------------------------------------

Biosimilars Struggle to Gain Market Share in the U.S., Analysis Shows

Biospace | Alex Keown
July 11, 2019

. . .The approval of biosimilar treatments has been supported at the highest levels as a means to increase competition in the market and help regulate some of the high costs of prescription drugs. However, despite the numerous approvals of biosimilars, they have not yet gained a significant stake in the marketplace.

. . . While it’s been a rocky road for biosimilars in the U.S., there is a fervent belief among some healthcare analysts and activists that increasing the use of these treatments will lead to vast savings. On Thursday, the Pacific Research Institute released a report that shows Americans could pocket more than $71 billion in savings if the use of biosimilars was expanded.

Read more . . . ([link removed])

============================================================
** ([link removed])
** ([link removed])
** ([link removed])
** ([link removed])
** ([link removed])
Copyright © 2019 *Pacific Research Institute*, All rights reserved.
You are receiving this email because you opted in via our website.

Our mailing address is:
101 Montgomery Street, Suite 1300, San Francisco, CA 94104

Want to change how you receive these emails?
You can ** update your preferences ([link removed])
or ** unsubscribe from this list ([link removed])
.